Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
New York, NY, Oct. 04, 2023 (GLOBE NEWSWIRE) -- BioPlus Acquisition Corp. (“BIOS” or the “Company”) (Nasdaq: BIOS) announced today that (i) BIOS, Avertix Medical, Inc. and certain other parties...
The Avertix Guardian™ System, the first and only FDA approved implantable heart attack warning system, now available at the Heart & Rhythm Institute of Trinity, extending their commitment to...
Recently served as Boston Scientific Executive Vice President and Global Chief Medical Officer Professor Meredith brings to Avertix over 35 years of cardiology experience and commitment to...
EATONTOWN, N.J. and ORLANDO, Fla., June 13, 2023 (GLOBE NEWSWIRE) -- Avertix Medical, Inc. (“Avertix” or the “Company”), formerly known as Angel Medical Systems, Inc., a company focused on...
- Transaction values Avertix at an enterprise value of $195 million- Avertix developed the Guardian™ System, the first and only FDA-approved solution designed to detect and warn patients of...
NEW YORK, Dec. 06, 2021 (GLOBE NEWSWIRE) -- BioPlus Acquisition Corp. (the “Company”) announced today that it priced its upsized initial public offering of 20,000,000 units at $10.00 per unit...
New York, NY, Dec. 02, 2021 (GLOBE NEWSWIRE) -- BioPlus Acquisition Corp. (the “Company”) announced today that it priced its upsized initial public offering of 20,000,000 units at $10.00 per...
BANNOCKBURN, Ill., Feb. 03, 2020 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the “Company” or “Option Care Health”) (NASDAQ: OPCH), the nation’s largest independent provider of home and...
DENVER, Dec. 26, 2019 (GLOBE NEWSWIRE) -- RLH Corporation (NYSE:RLH) today announced Robert Wolfe will be retiring from the Board of Directors on December 31, 2019. The Board of Directors has...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
